Convenient syntheses of the in vivo carbohydrate metabolites of mycophenolic acid: reactivity of the acyl glucuronide

2009 ◽  
Vol 50 (35) ◽  
pp. 4973-4977 ◽  
Author(s):  
Amy E. Jones ◽  
Helen K. Wilson ◽  
Paul Meath ◽  
Xiaoli Meng ◽  
David W. Holt ◽  
...  
2000 ◽  
Vol 46 (3) ◽  
pp. 365-372 ◽  
Author(s):  
Maria Shipkova ◽  
Ekkehard Schütz ◽  
Victor William Armstrong ◽  
Paul Dieter Niedmann ◽  
Michael Oellerich ◽  
...  

Abstract Background: The acyl glucuronide (AcMPAG) of mycophenolic acid (MPA) has been found to possess pharmacologic and potentially proinflammatory activity in vitro. To establish its pharmacologic and toxicologic relevance in vivo, a reversed-phase HPLC method was modified to simultaneously determine MPA, the phenolic MPA-glucuronide (7-O-MPAG), and AcMPAG. In addition, cross-reactivity of AcMPAG in the Emit assay for MPA was investigated. Methods: The procedure used simple sample preparation, separation with a Zorbax Eclipse-XDB-C8 column, and gradient elution. AcMPAG was quantified as 7-O-MPAG-equivalents. Results: The assay was linear up to 50 mg/L for MPA, 250 mg/L for 7-O-MPAG, and 10 mg/L for AcMPAG (r >0.999). Detection limits were 0.01, 0.03, and 0.04 mg/L for MPA, 7-O-MPAG, and AcMPAG, respectively. The recoveries were 99–103% for MPA, 95–103% for 7-O-MPAG, and 104–107% for AcMPAG. The within-day imprecision was <5.0% for MPA (0.2–25 mg/L), <4.4% for 7-O-MPAG (10–250 mg/L), and ≤14% for AcMPAG (0.1–5 mg/L). The between-day imprecision was <6.2%, <4.5%, and ≤14% for MPA, 7-O-MPAG, and AcMPAG, respectively. When isolated from microsomes, purified AcMPAG (1–10 mg/L) revealed a concentration-dependent cross-reactivity in an Emit assay for the determination of MPA ranging from 135% to 185%. This is in accordance with the bias between HPLC and Emit calculated in 270 samples from kidney transplant recipients receiving mycophenolate mofetil therapy, which was greater (median, 151.2%) than the respective AcMPAG concentrations determined by HPLC. AcMPAG was found to undergo hydrolysis when samples were stored up to 24 h at room temperature or up to 30 days at 4 °C or −20 °C. Acidified samples (pH 2.5) were stable up to 30 days at −20 °C. Conclusions: The HPLC and Emit methods for AcMPAG described here may allow investigation of its relevance for the immunosuppression and side effects associated with mycophenolate mofetil therapy.


2014 ◽  
Vol 59 (1) ◽  
pp. 25-37 ◽  
Author(s):  
Lin-Zhi Chen ◽  
John P. Sabo ◽  
Elsy Philip ◽  
Lois Rowland ◽  
Yan Mao ◽  
...  

ABSTRACTThe pharmacokinetics, mass balance, and metabolism of deleobuvir, a hepatitis C virus (HCV) polymerase inhibitor, were assessed in healthy subjects following a single oral dose of 800 mg of [14C]deleobuvir (100 μCi). The overall recovery of radioactivity was 95.2%, with 95.1% recovered from feces. Deleobuvir had moderate to high clearance, and the half-life of deleobuvir and radioactivity in plasma were ∼3 h, indicating that there were no metabolites with half-lives significantly longer than that of the parent. The most frequently reported adverse events (in 6 of 12 subjects) were gastrointestinal disorders. Two major metabolites of deleobuvir were identified in plasma: an acyl glucuronide and an alkene reduction metabolite formed in the gastrointestinal (GI) tract by gut bacteria (CD 6168), representing ∼20% and 15% of the total drug-related material, respectively. Deleobuvir and CD 6168 were the main components in the fecal samples, each representing ∼30 to 35% of the dose. The majority of the remaining radioactivity found in the fecal samples (∼21% of the dose) was accounted for by three metabolites in which deleobuvir underwent both alkene reduction and monohydroxylation. In fresh human hepatocytes that form biliary canaliculi in sandwich cultures, the biliary excretion for these excretory metabolites was markedly higher than that for deleobuvir and CD 6168, implying that rapid biliary elimination upon hepatic formation may underlie the absence of these metabolites in circulation. The lowin vitroclearance was not predictive of the observedin vivoclearance, likely because major deleobuvir biotransformation occurred by non-CYP450-mediated enzymes that are not well represented in hepatocyte-basedin vitromodels.


Hepatology ◽  
2012 ◽  
Vol 55 (6) ◽  
pp. 1673-1683 ◽  
Author(s):  
Qiuwei Pan ◽  
Petra E. de Ruiter ◽  
Herold J. Metselaar ◽  
Jaap Kwekkeboom ◽  
Jeroen de Jonge ◽  
...  

2015 ◽  
Vol 44 (3) ◽  
pp. 320-328 ◽  
Author(s):  
Y. Zhang ◽  
Y.-H. Han ◽  
S. P. Putluru ◽  
M. K. Matta ◽  
P. Kole ◽  
...  

2000 ◽  
Vol 33 (2) ◽  
pp. 107-113 ◽  
Author(s):  
Eberhard Wieland ◽  
Maria Shipkova ◽  
Ulrike Schellhaas ◽  
Ekkehard Schütz ◽  
Paul Dieter Niedmann ◽  
...  

Biochimie ◽  
2007 ◽  
Vol 89 (3) ◽  
pp. 393-402 ◽  
Author(s):  
Abdul R. Asif ◽  
Victor W. Armstrong ◽  
Antje Voland ◽  
Eberhard Wieland ◽  
Michael Oellerich ◽  
...  

2008 ◽  
Vol 30 (3) ◽  
pp. 282-291 ◽  
Author(s):  
Lillian S L Ting ◽  
Nilufar Partovi ◽  
Robert D Levy ◽  
K Wayne Riggs ◽  
Mary H H Ensom

2010 ◽  
Vol 43 (1-2) ◽  
pp. 208-213 ◽  
Author(s):  
Horst Feichtiger ◽  
Eberhard Wieland ◽  
Victor W. Armstrong ◽  
Maria Shipkova

2021 ◽  
Author(s):  
Fan-Fan Shang ◽  
Mei-Yuan Wang ◽  
Jiang-Ping Ai ◽  
Qing-Kun Shen ◽  
Hong-Yan Guo ◽  
...  

Abstract Nineteen mycophenolic acid (MPA) derivatives were designed and synthesized, and their anti-Toxoplasma activity evaluated for the first time. Among them, N-propylimidazole-modified compound E5 demonstrated the strongest activity, and the IC50 against HFF-1 (Human Foreskin Fibroblasts-1) cells following infection with T. gondii is 80.9 μM (MPA-211.5 μM) and its selectivity value is 2.2 (MPA-1.2). In vivo experiments, E5 significantly inhibited the proliferation of tachyzoites in the abdominal cavity of mice acutely infected with T. gondii (inhibition rates 46.7%), and this inhibitory effect was greater than that of spiramycin (inhibition rates 31.3%) and MPA (inhibition rates 15.9%), this indicated that E5 had significant protective effects on the host during acute Toxoplasma infection. In addition E5 significantly reduced the levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in the serum of infected mice, significantly increased the level of glutathione (GSH) in the liver, and significantly reduced the level of malondialdehyde (MDA), indicating that it has a significant hepatoprotective effect against T. gondii infection. Similarly, E5 can relieve hepatomegaly and splenomegaly induced by acute Toxoplasma infection. Spiramycin aggravated appetite loss in infected mice, while E5 did not. In summary, the results indicated that E5 has potential as a candidate anti-T. gondii drug.


Sign in / Sign up

Export Citation Format

Share Document